Skip to main content
Premium Trial:

Request an Annual Quote

Core Centers to Reap $100M from NIH Stimulus

NEW YORK (GenomeWeb News) – Around $100 million from the economic stimulus package funds will go to build up centers for shared biomedical research resources, the National Institutes of Health said today.

These Biomedical Research Core Centers will receive grants to support shared resources for use by researchers from different disciplines that are pursuing a multidisciplinary approach to a joint research effort, or to those who are from one specialty area who are focusing on a common problem.

The funding program will give money to develop and acquire the resources necessary to conduct relevant research projects, including start-up packages for newly independent investigators.

The Core Centers will bring together investigators and resources to focus on one common research problem that is of importance to the institution and appropriate to NIH's mission. The aim is to create centers that will serve as the locus for projects.

These projects should be based on the existing strengths within the institutions applying and should complement and expand their research activities, said NIH.

NIH also is interested in receiving applications from institutions seeking to develop core centers that would further bioethics research.

The specific funding levels will vary among the participating centers, as will the duration of the awards.

More information on the funding opportunity can be found here.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.